Genome-Wide Association Study (GWAS) meta-analyses have identified a strong association signal for lung function, which maps to a region on 4q24 containing two oppositely transcribed genes: glutathione S-transferase, Cterminal domain containing (GSTCD) and integrator complex subunit 12 (INTS12). Both genes were found to be expressed in a range of human airway cell types. The promoter regions and transcription start sites were determined in mRNA from human lung and a novel splice variant was identified for each gene. We obtained the following evidence for GSTCD and INTS12 co-regulation and expression: (i) correlated mRNA expression was observed both via Q-PCR and in a lung expression quantitative trait loci (eQTL) study, (ii) induction of both GSTCD and INTS12 mRNA expression in human airway smooth muscle cells was seen in response to TGFβ1, (iii) a lung eQTL study revealed that both GSTCD and INTS12 mRNA levels positively correlate with percent predicted FEV 1 , and (iv) FEV 1 GWAS associated SNPs in 4q24 were found to act as an eQTL for INTS12 in a number of tissues. In fixed sections of human lung tissue, GSTCD protein expression was ubiquitous, whereas INTS12 expression was predominantly in epithelial cells and pneumocytes. During human fetal lung development, GSTCD protein expression was observed to be highest at the earlier pseudoglandular stage (10-12 weeks) compared with the later canalicular stage (17-19 weeks), whereas INTS12 expression levels did not alter throughout these stages. Knowledge of the transcriptional and translational regulation and expression of GSTCD and INTS12 provides important insights into the potential role of these genes in determining lung function. Future work is warranted to fully define the functions of INTS12 and GSTCD.
Introduction
Forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), and the ratio of FEV 1 to FVC (FEV 1 /FVC) are commonly used to assess pulmonary function and these measurements are integral to the diagnosis of chronic obstructive pulmonary disease (COPD). Reduced FEV 1 /FVC defines airway obstruction, whereas reduced FEV 1 grades the severity of airway obstruction [1] . These measures also predict population morbidity and mortality [2] .
Pulmonary function is determined both by environmental and genetic factors. Tobacco smoking is the major environmental risk factor for the development of COPD in the developed world. A genetic contribution to pulmonary function is well established with heritability estimates reaching as high as 77% for FEV 1 [3] . Three large scale meta-analyses of genome-wide association studies (GWAS) of lung function measures have recently been published [4] [5] [6] : these studies identified a total of 26 novel loci associated with either FEV 1 or FEV 1 /FVC. Genome-wide interaction analyses with smoking later identified three additional regions of potential importance for lung function [7] . One of the strongest association signals identified was with intronic Single Nucleotide Polymorphisms (SNPs) in a region at 4q24 containing two oppositely transcribed genes: glutathione S-transferase, C-terminal domain containing (GSTCD) and integrator complex subunit 12 (INTS12). In the SpiroMeta study [5] , SNP rs10516526 in intron 5 of GSTCD was associated with FEV 1 (P=2.18x10 -23 in the joint metaanalysis of discovery and replication cohorts (n=53,309)). In the combined SpiroMeta CHARGE meta-analysis with larger sample size (discovery n=48,201), SNP rs10516526 also showed the strongest association in the 4q24 locus for FEV 1 (P=4.75x10 -14 ) [6] . Subsequent reports by SpiroMeta investigators and others have also implicated this locus for association with COPD [8, 9] .
At present, little is known about the potential function of GSTCD -all four entries on PubMed are related to recent GWAS studies [4, 5, 8, 9] . GSTCD is so named because of homology with the glutathione S-transferase (GST) super family of enzymes [10] . GSTs are also involved in the detoxification of products of oxidative stress [11] and synthesis of steroid hormones. They also have an increasingly appreciated role in cell signalling pathways including regulation of Jun N-terminal kinase and the modulation of ryanodine receptor calcium channels [10, 12] . However, GSTCD lacks key functional domains important for GST activity. Although still only appearing in a handful of (largely GWAS-related) publications [4, 8, 13] , more is known about the function of INTS12, which is a subunit of the Integrator complex. This complex associates with the C-terminal domain of RNA polymerase II large subunit and mediates 3` end processing of small nuclear RNAs [14] .
Additional evidence linking GSTCD to variation in lung function came from a study reporting human lung mRNA correlation with lung function [15] . In this study, which undertook genome-wide expression profiling, GSTCD mRNA levels were associated with percent predicted FEV 1 (Spearman correlation=0.44, P=0.001) and the FEV 1 /FVC ratio (Spearman correlation=0.48, P=0.0002) [15] . This, and the fact that the 4q24 locus has the strongest novel association with lung function in the multiple GWAS meta-analyses conducted so far, have provided the rationale to further investigate this locus to unravel the mechanisms underlying this association.
Here we report the genetic architecture of GSTCD and INTS12, and show that both genes are expressed in a range of cell types present in the lung. We report one novel splice variant for each gene. Furthermore we show that the genomewide significant SNPs at 4q24 act as expression quantitative trait loci (eQTL) for INTS12, and provide evidence that the peak association signal maps to a region rich in elements likely to be important for transcriptional regulation of these genes. Interestingly, these appear to be coordinately regulated in the lung. Expression levels were also shown to correlate with lung function measures. Finally, we describe the expression of GSTCD and INTS12 proteins in human lung tissue and assess how expression is altered during human fetal development.
Results

Gene arrangement via PCR and RACE
Using cDNA synthesised from RNA extracted from total lung, human airway smooth muscle (HASM) cells and normal human bronchial epithelial cells (HBEC), Reverse Transcription (RT)-PCR was initially performed to investigate whether gene arrangements are consistent with those reported by NCBI (the National Center for Biotechnology Information). For both GSTCD and INTS12 a novel splice variant was discovered via this method (named here "variant 3"). Figure 1 outlines schematically the two published variants in addition to the novel variant 3 in each case. The SpiroMeta genome-wide significant SNPs for association with FEV 1 in this locus are annotated on the schematic in Figure 1 along with the relevant association statistical P values [5] .
To confirm published or reveal novel transcription start site (TSS) s for both GSTCD and INTS12, Rapid Amplification of cDNA Ends (RACE) was performed. For GSTCD, a total of 30 clones were sequenced and analysed. 5' RACE confirmed the presence of variant 2 (NM_024751.2) in 13 of these (43%), albeit with multiple TSSs spanning a region of 50bp; minimum +3, maximum +53bp distance relative to RefSeq (TSS) at 106629941 (hg build 37) ( Figure S1A ). The annotated nucleotide sequence showing TSSs in both GSTCD and INTS12 can be found in Figure S1 . Interestingly, variant 1 of GSTCD (NM_001031720.2) was not identified in any of the 30 RACE clones analysed. Sequence reads did confirm the novel variant 3 identified via RT-PCR for GSTCD in 17 clones out of the 30 analysed (56%) ( Figure S1B ). Variant 3 sequence mapped to the first exon of variant 2 and the second exon of variant 1. Three different TSSs were identified in variant 3 spanning a region of 27bp; the first was identical to the RefSeq exon 1 (3/30 clones = 10%), the second was the most common (12/30 clones = 40%) and had a 10bp shorter exon 1, the third and least frequent had a 27bp shorter exon 1 (2/30 clones= 6.7%) ( Figure S1A and B) .
To confirm the absence of exon 1 of GSTCD variant 1 in the lung tissue, a different RT-PCR protocol was designed with primers spanning this exon and a sequence in exon 3, common to both variants. No PCR product for this assay was detected in a panel of airway-related cell types after 40 cycles of PCR ( Figure S2 ).
For INTS12, the 5' RACE using RNA from lung tissue confirmed the presence of variant 2 with multiple TSSs over a region of ~30bp; minimum 36 and maximum 60bp upstream (distance relative to the RefSeq build 37 TSS at 106629881). Variant 1 (NM_020395.3) was not observed in any of the 31 clones analysed. The most common variant 2 transcript identified was a 60bp truncated first exon (18/31 clones = 58%), relative to the RefSeq. 50bp and 36bp truncations of exon 1 were also identified with frequencies of 23 and 19%, respectively ( Figure S1C ).
As shown in Table 1 , both GSTCD and INTS12 feature on NCBI as existing in two variants. GSTCD variants 1 and 2 encode two proteins differing in length by 87 amino acids. This is the result of a truncated second exon meaning that amino acids 55 to 141 of variant 1 are absent in variant 2. Unlike GSTCD, the two INTS12 transcripts both encode the same protein. If translated, the INTS12 variant 3 would result in a truncated protein of 237 residues (versus 462 residues for variants 1 and 2), due to a premature translational stop codon present in the additional exon between exons 5 and 6 (shown boxed in red in Figure 1 ). The resulting protein isoform retains the PHD-type zinc finger, but lacks the serine-rich region. Searches to identify proteins sharing homology with the GSTCD and INTS12 variants are shown in Table S1 (A-C) and summarised in the discussion.
Re-sequencing of the GSTCD/INTS12 region
In two separate studies (results currently unpublished), resequencing experiments were performed to investigate the effects of novel or rare SNPs on lung function. We extracted information on SNPs measured in these studies within GSTCD and INTS12 to identify whether there were any SNPs which were novel or not included in the previously used (i.e. HapMap) Figure 1 . Genetic architecture of the region containing both GSTCD and INTS12 genes. The top panel depicts gene arrangements previously reported in NCBI, build 37, whereas the lower panel shows novel variants identified in lung. V1, 2, 3 refer to splice variants 1, 2 and 3 for each gene. Open boxes represent exons and connecting black lines represent introns. Also illustrated are the locations of Single Nucleotide Polymorphisms (SNPs) meeting genome-wide association (P≤5x10 -8 ) for FEV 1 in previously reported analyses of the SpiroMeta consortium [5] . Highlighted in red is the sentinel SNP rs10516526 that was associated with FEV 1 (P=2.18 x 10 -23 in all stage analyses) [5] . Translation start codons (ATG) are shown boxed in green and stop codons (TAA) boxed in red. or next generation (i.e. 1000 Genomes Project) SNP imputation reference panels used for genome-wide association studies of the genetic determinants of lung function. An exome resequencing project using DNA from 100 individuals with normal FEV 1 despite many years of heavy smoking (see Table S2A ) identified 1 non-synonymous SNP (rs146172950) and 1 synonymous SNP (rs144650579) in the coding region of INTS12 which were listed in dbSNP v137 but which were not in the 1000 Genomes Project imputation reference panel [16] . All SNPs appeared in the 1000 Genomes Project imputation reference panel in exonic GSTCD. In addition a targeted sequencing study in both controls and subjects with COPD that focused on 26 regions known to affect lung function [4, 5, 9 ] (see Table S2B ) identified two intronic SNPs in GSTCD that do not appear in the 1000 Genomes Project imputation reference panel. One of them is listed in dbSNP v137 (rs113987854) and the other is not. None of these SNPs were in the widely used HapMap imputation panels and so would not have been studied in imputed genome-wide association studies undertaken to date. These data provide some evidence for variation in GSTCD that is not currently included in the next generation of widely used imputation reference panels of SNPs.
GSTCD/INTS12 in the University of California Santa Cruz (UCSC) Genome Browser
Due to the close proximity of the GSTCD and INTS12 genes, we investigated current knowledge regarding the regulation of this region through bioinformatic searches including data and tracks generated from the ENCODE project [17] . Figure 2 shows the "Regulation" tracks from the UCSC Genome Browser (http://genome.ucsc.edu/). It is interesting to note the histone modification activity in this region is expressed as acetylation of lysine 27 of the H3 histone protein; this is usually associated with enhanced transcription and active promoters in mammalian cells [18] . Also shown in Figure 2 is a CpG island (bottom track). An expansion of this region reveals the CpG island to be 639bp long: this encompasses the intergenic region between GSTCD and INTS12, and parts of the first exon of both genes. The UCSC Genome Browser defines a CpG island as a region of at least 200bp, with a GC percentage >50%, and an observed/expected CpG ratio >60%. CpG islands are classically associated with transcription start sites and are found in ~70% of annotated promoters [19] .
Expression of GSTCD and INTS12 mRNA in human airway cells and lung tissue
We have previously reported that GSTCD is identified in lung and airway-related cell types at the mRNA level using RT-PCR [5] , however the presence of INTS12 was not assessed. The relative expression of GSTCD and INTS12 was therefore determined in a panel of airway-related cell types using quantitative RT-PCR (Q-PCR). Whole human lung, cultured HASM cells, cultured HBEC and peripheral blood mononuclear cells (PBMC) were studied ( Figure 3A ). Mean expression data are presented relative to the whole lung sample for each tissue/ cell type. The highest expression of both GSTCD and INTS12 was seen in HBEC, with GSTCD showing relatively higher expression in this cell type than INTS12. The lowest GSTCD expression was detected in PBMC, while for INTS12 the lowest expression was detected in the whole lung samples. Ct values observed for GSTCD and INTS12 were generally comparable, and the efficiency standard curves for both genes were also similar (data not shown). Interestingly, delta Ct values of both genes presented as a scatter plot ( Figure 3B ) showed a moderate degree of correlation (r=0.64, P<0.0001) suggesting expression may be coordinately regulated. To verify this, we investigated the correlation between the GSTCD and INTS12 probe sets in 1,111 human lung specimens from the lung eQTL study [20] . The results presented in Table 2 show good positive correlation between the GSTCD and INTS12 probe sets in agreement with that observed via Q-PCR. The strongest correlation observed was between probe set 100139146_TGI_at (INTS12) and probe set 100312817_TGI_at (GSTCD) (r=0.18, P=6.7E-10); a scatter plot of these data is shown in Figure 3C .
Altered expression of GSTCD and INTS12 mRNA by TGFβ1
Further evidence of coordinated expression came from a series of experiments to determine which signalling pathways could modulate mRNA levels of GSTCD and INTS12 in HASM and HBEC, as assessed by Q-PCR. A range of agents was selected, each known to mediate common cell signalling pathways, particularly with a focus on those associated with airway dysfunction. The agents utilised were bradykinin (elevator of intracellular Ca 2+ ), forskolin (activator of adenylyl cyclase and hence the pro-relaxant cyclic AMP pathway), lipopolysaccharide (LPS) (used as a mimic of bacterial infection), transforming growth factor β1 (TGFβ1) (a key cytokine, found to be elevated in airway inflammation, and in COPD) and the Extracellular Signal-Regulated Kinase (ERK) inhibitor U0126. None of the agents induced a significant alteration in the levels of mRNA expression of either gene in HBEC. In addition, of all the panel of reagents utilised, only exposure to TGFβ1 induced a significant change in mRNA expression in HASM cells, however this was observed for both genes ( Figure 4 ). Significant increases in mRNA expression in HASM cells were observed following 24h exposure to TGFβ1 in both GSTCD (1.56 ± 0.2 fold cf vehicle control, n=5, P<0.05) and INTS12 (2.26 ± 0.3 fold cf vehicle control, n=5, P<0.01) while a significant increase in INTS12 was also observed following 4h TGFβ1 exposure (2.0 ± 0.2 fold cf vehicle control, n=5, P<0.05). To investigate the possible transcriptional mechanisms driving these observed differences, ENCODE data from the UCSC Genome Browser were utilised to investigate transcription factor binding as determined through ChIP-seq (chromatin immunoprecipitation with antibodies specific to the transcription factor followed by sequencing of the precipitated DNA). A number of transcription factor binding sites were identified in the intergenic region between GSTCD and INTS12 and in the gene 5' regions (Table S3 ) and the potential relevance of these is covered in the Discussion.
Identifying eQTL in the GSTCD/INTS12 locus
To gain further insight into the mechanisms underlying the GWAS signal on 4q24, we investigated the presence of eQTL in this locus using publically available eQTL sources, and also through access to a lung tissue-specific eQTL dataset in collaboration with the lung eQTL study group [20] .
We investigated eQTL in the 4q24 locus via the eQTL website at http://www.hsph.harvard.edu/liming-liang/software/ eqtl/ using the lymphoblastoid cell line dataset from Liang et al. [21] . Interestingly, using this dataset we identified an eQTL for INTS12 that met the 0.05 false discovery rate (FDR) (probe set 218616_at). There were no significant eQTL for GSTCD, NPNT or FLJ20184 ( Figure S3A ).
In addition, we investigated eQTL in the 4q24 region using the University of Chicago eQTL website at http:// eqtl.uchicago.edu/Home.html which hosts a browser summarising results from a collection of published eQTL studies. The results shown in Figure S3B , are similar to the Liang et al., data suggesting the presence of eQTL for INTS12 in eQTL studies utilising different tissue types. We then extracted the associations of INTS12 eQTL with FEV 1 in the SpiroMeta dataset, and interestingly the majority of INTS12 eQTL show genome-wide significant associations with FEV 1 in the SpiroMeta dataset. The INTS12 eQTL and their associations with FEV 1 are shown in Table 3 . Additionally, we checked the potential function of INTS12 eQTL in the ENCODE Figure 3A from human airway smooth muscle (HASM) cells, human bronchial epithelial cells (HBEC), peripheral blood mononuclear cells (PBMC) and lung were correlated using a scatter plot. The correlation coefficient between these measures was r=0.8, P<0.0001. C: Correlation between GSTCD and INTS12 mRNA levels in the lung. The scatter plot shows a positive correlation between the GSTCD and INTS12 probe sets as investigated in the lung eQTL study [20] . doi: 10.1371/journal.pone.0074630.g003 dataset using HaploReg v2. These eQTL appear to span regions with either known protein binding motifs, enhancers, promoters or DNase hypersensitivity sites. Results are shown in Table S4 . In collaboration with the lung eQTL study [20] we aimed to identify eQTL for GSTCD and INTS12 in the human lung using a dataset of genome-wide genotypes and gene expression profiles from the lungs of 1,111 individuals that has recently been published [20] . There were no lung eQTL for GSTCD or INTS12 that pass the 0.1 FDR threshold set in the lung eQTL study. The eQTL identified for GSTCD and INTS12 in the lung are shown in Figure S4 which suggest a stronger eQTL signal for INTS12, albeit not significant when correcting for multiple comparisons.
Correlation of GSTCD and INTS12 mRNA levels in the lungs with percent predicted FEV 1 Three probe sets targeting GSTCD and one probe set for INTS12 were utilised in the lung eQTL study. The correlation measures of these probe sets with percent predicted FEV 1 are shown in Figure 5 . One of the GSTCD probe sets (100156283_TGI_at, r=0.14, P=6.74x10 -5 ) and the INTS12 probe set (r=0.13, P=1.95x10 -4 ) show reasonable correlation with percent predicted FEV 1 , although the correlation was more statistically significant with the GSTCD probe set. Moreover, the direction of correlations is such that higher mRNA levels correlate with better lung function indicated by higher percent predicted FEV 1 . Table S5 shows the demographics of the individuals which participated in this study. 
Expression of GSTCD and INTS12 protein in human lung
Having dissected the genetic architecture of GSTCD and INTS12 and explored their regulation at the mRNA level, we next investigated expression at the protein level in the human airways. In addition to utilising samples from non-diseased sections of human lungs, we assessed expression of both proteins in individuals with COPD and also in human lung at a range of fetal developmental stages. Figure 6 shows representative images of the expression of GSTCD (6A) and INTS12 (6B) in control donors (panels a and e) and in lung samples from individuals with COPD (panels b and f). In controls, GSTCD was observed to be expressed ubiquitously, being most evident in the pneumocytes of alveolar regions ( Figure 6A , image a) and in the bronchial epithelium ( Figure 6A , image e). In all cell types, expression was observed to be predominantly cytoplasmic. INTS12 expression in controls and individuals with COPD was most evident in the nuclei of alveolar pneumocytes ( Figure 6B , images a and b) and also in bronchial epithelial cells ( Figure 6B , images e and f). When expression was investigated through different stages of fetal development, the earliest embryonic samples (19 days) exhibited weak nuclear and cytoplasmic immuno-positivity for GSTCD ( Figure 6C , top panel, images a and b), while embryonic samples at 23 days development (images e and f) showed strong protein expression in the developing blood vessels and the outer region of the developing bronchioles. Strong GSTCD expression was observed throughout the pseudoglandular stage (images g-j), where expression was noted in the nuclei of the developing pneumocytes of the early bronchiole. Although high protein expression was still observed in the blood vessels in tissue from the canalicular stage, at this stage expression in the pneumocytes appeared to be reduced compared with earlier developmental stages (images k-l).
When comparisons were made between samples, INTS12 expression remained generally consistent throughout all 3 developmental stages of fetal lung development, although in 2 out of the 6 early embryonic samples expression was somewhat reduced ( Figure 6C, panel 2, images a and c) . Expression was localised to the nucleus in most airway cell types ( Figure 6C, panel 2) . Expression profiling of GSTCD and INTS12 was also investigated using the BioGPS portal and this revealed ubiquitous expression [22] .
Comparison of GSTCD and INTS12 mRNA and protein levels through lung development
To assess whether the expression of GSTCD and INTS12 through lung development at the protein level correlated with that found at the mRNA level, a previously reported dataset was mined to specifically interrogate these genes [23] . This dataset contains samples analysed using gene expression arrays to investigate expression patterns in the developing human lung, specifically throughout the pseudoglandular (7-16 weeks) and the canalicular (17-26 weeks) stages. While INTS12 expression was not observed to be altered significantly between these stages, interestingly GSTCD expression significantly decreased with age between the pseudoglandular and canalicular stages (Table S6) as we also had observed at the protein level ( Figure 6C , panel 1, pseudoglandular images g-j, canalicular images k-l).
Discussion
The aims of the studies described in this manuscript were to (i) define the genetic architecture surrounding the SNPs at the GSTCD/INTS12 locus at 4q24 previously found to be strongly associated with lung function, (ii) assess how GSTCD and INTS12 gene expression is regulated, (iii) analyse GSTCD and INTS12 protein expression in non-diseased lung tissue and lung tissue from individuals with COPD and (iv) assess whether GSTCD or INTS12 protein expression changes during fetal development.
The main conclusions were that lung function associated SNPs in the region act as eQTL for INTS12 in multiple tissue types including lymphoblastoid cell lines (LCL), brain and liver Table S5 for patient demographics). and that both genes were widely expressed in cell types relevant to airway function, including airway smooth muscle cells and epithelial cells with evidence for coordinated gene expression of GSTCD and INTS12. Finally mRNA levels in the lung of both genes were correlated with lung function. It seems likely that the association signal in this region is explained by altered gene expression of INTS12 or GSTCD, or potentially both genes.
Existing evidence suggests that transcript levels of GSTCD are associated with variability in lung function from a study that investigated lung mRNA expression levels among individuals with variable degrees of airway obstruction [15] . This was confirmed when we utilised data from a larger sample set that aimed to identify lung eQTL and where lung function measures were available on the majority of participants (n=848) ( Figure  5 ). Findings from this study suggest a strong correlation between a probe set targeting GSTCD with percent predicted FEV 1 and also, between the INTS12 probe set and percent predicted FEV 1 .
It was particularly interesting that GSTCD protein expression was observed to be altered through lung development, decreasing between the pseudoglandular and canalicular stages. Importantly, this correlates with a decrease in GSTCD at the mRNA level between these same developmental stages, as revealed by mining and specifically analysing the results of a study previously reported by Melén et al. [23] . That protein and mRNA levels of GSTCD are relatively higher in the pseudoglandular stage when compared with the canalicular stage is significant as it is through this stage of development that airway smooth muscle cells, mast cells, T-lymphocytes and dendritic cells all begin to appear within the lung parenchyma [23] . Conversely, the reduction in GSTCD in the canalicular phase coincides with alteration of the epithelium and the surrounding mesenchyme.
Very little is known about the potential function of GSTCD. As suggested by the name, part of this protein shares homology with a GST motif which is present in a number of other proteins. A protein homology search using NCBI BLAST identified a number of other proteins sharing similar motifs with GSTCD variants (Table S1A and 1B) with the closest match being Eukaryotic Translation Elongation Factor 1, also known as Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein 3 (AIMP3). AIMP3 is an auxiliary component of the macromolecular aminoacyl-tRNA synthase complex which is reported to act as a molecular hub, linked to diverse signalling pathways [24] . Also found to share homology with GSTCD were isoforms of the Titin protein. Titin, previously known as Connectin, is important in striated muscle contraction although the expression and function of specific Titin isoforms have also been reported in a range of smooth muscle types [25, 26] . Interestingly, we also found homology with human Chloride intracellular channel protein (hCLIC) 6. The role of hCLIC proteins in the airways is unknown, although chloride homeostasis has been shown to be important in a range of respiratory conditions such as Cystic Fibrosis.
INTS12 is the smallest subunit of the Integrator complex [14] that associates with the C-terminal domain of the largest subunit of RNA polymerase II (RNAPII) at the promoter of small nuclear (sn) RNA genes, where it mediates 3' end processing of snRNAs. RNAi-mediated deletion of INTS12 in Drosophila S2 cells leads to snRNA mis-processing [27] , suggesting a key role for INTS12 within the Integrator complex. INTS12 possesses a highly conserved PHD-type zinc finger domain (a motif often found in proteins involved in gene regulation), but surprisingly this feature is not necessary for the snRNA processing function of INTS12 in S2 cells [28] . Instead, a short 45 amino acid N-terminal domain appears both necessary and sufficient to re-establish Integrator function in INTS12-depleted cells and to mediate the binding and stabilisation of the larger INTS1 subunit [28] . A protein homology search did not provide additional insight into previously unrealised function (Table  S1C ). The role of INTS12 in the mammalian respiratory system has yet to be investigated, but a fundamental role for INTS12 in mammalian cellular function is suggested by preliminary evidence of pre-weaning lethality in transgenic mice lacking the INTS12 gene (http://www.sanger.ac.uk/mouseportal/search? query=colonyprefix:MALX).
From both experimental and in silico searches, some interesting observations can be made regarding the arrangement and regulation of GSTCD and INTS12. The data presented suggest that under certain conditions in cells derived from adult lung tissue, GSTCD and INTS12 are co-expressed. This was observed in the Q-PCR expression studies performed in airway-related cell types and PBMC ( Figure 3B ) and was confirmed in microarray data from the lung eQTL study ( Figure  3C ). In addition the expression changes in response to TGFβ1 treatment also seem to be coordinated (Figure 4) . Data from Zebrafish suggest that the mean correlation coefficient r of all the neighbouring gene pairs is 0.075, compared to r=0.03 in a randomised genome of the same genes and expression values [29] . Thus our observed correlation coefficient of 0.64 suggests that GSTCD and INTS12 are correlated to a greater extent than would be anticipated by chance for neighbouring genes.
The coordinated expression among GWAS signal is interesting. It may suggest that trait associated variants reside in regulatory regions that control the expression of multiple genes, and it is possible that these regulated genes are part of molecular pathways or networks underlying the trait. Furthermore, the co-expression could be due to genes sharing a bidirectional promoter, which are common in the human genome; it is estimated that divergent genes regulated by these account for 11% of all human genes [30, 31] . Bidirectional promoters typically (i) lack TATA boxes (only 8% of bidirectional promoters contain a TATA box), (ii) have a high GC content (66%), (iii) are enriched in CpG islands (77%) [31, 32] , and (iv) about two thirds of non-overlapping bidirectional promoters were found to be shorter than 300 bp in length [31] . The GSTCD/INTS12 region exhibits many of these characteristics: (i) they are divergent genes transcribed in opposite directions, (ii) they were shown to be expressed in all airway cell types tested, (iii) mRNA expression shows some degree of correlation, (iv) the regions upstream of their TSS lacked TATA boxes, and (v) the UCSC Genome Browser suggests the intergenic region contains a CpG island and has histone modification activity indicating active transcription. However, the lack of a clear correlation between GSTCD and INTS12 expression patterns during lung development in utero suggests additional, gene-specific regulatory pathways may also exist.
The observed regulation by TGFβ1 is of particular relevance within the context of several airway diseases, particularly COPD and Idiopathic Pulmonary Fibrosis, in which TGFβ1 is a key driver of fibrosis and extracellular matrix deposition. Perhaps surprisingly, in silico analyses of putative transcription factor binding sites did not reveal any matches between the intergenic GSTCD/INTS12 shared promoter region and Smadinduced transcription sites. However, interestingly we did identify a number of other matches to transcription factors including Serum Response Factor (SRF), NFκB, Glucocorticoid Receptor (GR) and STAT3 which gives potential mechanistic insight into regulatory pathways for these genes (see Table  S3 ). In human lung fibroblasts, SRF expression is dramatically increased following exposure to TGFβ [33] thus this is a likely mechanism for the TGFβ1-induced increase in GSTCD and INTS12 mRNA in airway smooth muscle cells. STAT3 has recently been suggested to be a central mediator of pulmonary fibrosis via dysregulation of epithelial-mesenchymal communication [34] . GR-mediated signalling occurs via both gene repression and activation and it is unclear which contributes to the anti-inflammatory effects of glucocorticoids. However GR is able to associate directly with NFκB, for which a consensus site was also observed in the intergenic GSTCD/ INTS12 region.
Taken together, the evidence presented in this paper provides the first insight into the expression and regulation of GSTCD and INTS12 in the airways. Whilst other genes at this locus (notably NPNT) may also potentially contribute, the evidence provided here suggests an important role for GSTCD and/or INTS12. Knowledge of the transcriptional and translational regulation and expression of these genes should provide important insights into the underlying cause of the observed strong association signal with lung function at this locus on 4q24.
Materials and Methods
Ethics statement
All work was conducted with full ethical approval from the sites involved. Details are given in the following sections.
Cell culture, treatment and preparation of total RNA
Primary human airway smooth muscle (HASM) cells were isolated and prepared from three different donors then cultured as described previously [35] . Ethical approval for the use of primary cells was obtained from the Nottingham University Hospitals local ethical committee (ref. EC00/165). Written informed consent from the donor was obtained for use of this sample in research.
Undifferentiated, adherent human bronchial epithelial cells (HBEC) from three donors were commercially sourced from Lonza (Basel, Switzerland), and cultured in bronchial epithelial growth medium (BEGM) as per manufacturer's instructions.
For analysis of altered gene expression via exposure to a range of stimuli, cells were grown to 70 80% confluency and the media changed to serum-free DMEM (for HASM) or BEGM lacking hydrocortisone, Epithelial Growth Factor and epinephrine (for HBEC) for 24h. Cells were exposed to the following stimuli for 4h or 24h at the concentrations given: TGFβ1 (10ng/ml), forskolin (10µM), U0126 (10µM), bradykinin (1µM) and Lipopolysaccharide (LPS) (E. coli 026:B6) (1µg/ml). All stimuli were obtained from Sigma Aldrich (Gillingham, UK) .
For downstream analysis, cells were lysed and RNA extracted using silica columns (RNeasy mini kit, Qiagen, Crawley, UK). Total RNA was commercially obtained for peripheral blood mononuclear cells (PBMC) of three donors from 3H Biomedical (Uppsala, Sweden), and lung RNA from three donors was obtained from Applied Biosystems/Ambion (Warrington, UK).
5' and 3' Rapid Amplification of cDNA Ends (RACE)
RACE-ready cDNA was synthesised from total RNA (1µg) from lung, HASM, undifferentiated HBEC and PBMC using the GeneRacer kit as directed (Invitrogen, Paisley, UK). 5' and 3' RACE used GeneRacer primers and gene-specific nested primers for amplification. PCR products generated were also cloned to further clarify the exon structure of the gene. Both RACE and PCR products were sequenced using BigDye 3.1 (Applied Biosystems) in conjunction with an ABI 310 DNA sequencer. Sequences were aligned to the human database using the BLAST alignment tool (blast.ncbi.nlm.nih.gov).
Real-time PCR (Q-PCR)
mRNA levels of GSTCD/INTS12 were quantified using a series of Q-PCR assays. Amplicons spanning exons 5-6 of GSTCD and exons 7-8 of INTS12 were used with FAM/ TAMRA labelled TaqMan probes. cDNA was synthesised using Superscript II (Invitrogen) and random hexamer primers as per manufacturer's instructions. RNA (1µg) was used in a 20µl reverse transcription reaction Q-PCR was performed using TaqMan gene expression master mix (Applied Biosystems) and 18S ribosomal RNA endogenous control (Applied Biosystems). Data were corrected to the 18S housekeeper using the 2 Dublin, Ireland) and hydrated using decreasing concentrations of ethanol. Antigen retrieval was performed in a steamer for 20 minutes in sodium citrate buffer (pH 6.0), followed by an endogenous peroxidase block for 5 minutes (Dako, Cambs, UK). Slides were incubated with either a mouse polyclonal anti-GSTCD antibody (H00079807, Abnova, Taiwan, China) (1:100) or a rabbit polyclonal anti-INTS12 antibody (HPA035772, Sigma Prestige Antibodies, Dorset, UK) (1:800) for 1 hour at room temperature. Additional slides were stained in parallel with normal mouse or rabbit IgG as respective matched isotype controls (Invitrogen). The Dako Chemate Envision Detection Kit (Dako) with DAB chromogen was used for detection. Sections were then counterstained with Mayer's Haematoxylin (Surgipath, Cambs, UK), dehydrated and a coverslip mounted using Vectamount (Vector Laboratories, Peterborough, UK). Human liver or tonsil tissues were used as positive controls for GSTCD and INTS12 staining, respectively, whilst a negative control consisted of primary antibody substituted for antibody diluent. Results were visualised using an Olympus BX14 light microscope.
Statistical analysis
Differences in expression in Q-PCR experiments were evaluated using ANOVA and Dunnett's or Tukey's post hoc test as appropriate. Data were analysed using Prism v.5.01 (GraphPad software, La Jolla, CA). P<0.05 was considered a statistically significant threshold.
Bioinformatics
Protein BLAST, BLASTP (http://blast.ncbi.nlm.nih.gov/ Blast.cgi?PAGE=Proteins), was used to align homologous protein sequences against GSTCD and INTS12 protein isoforms obtained from NCBI.
The region containing GSTCD-INTS12 was also investigated using the UCSC genome Browser [36] (accessed at http:// genome.ucsc.edu/ in January 2013). More specifically, annotations features from the ENCODE (The Encyclopaedia of DNA Elements) Browser tracks [17] were used based on experimental data from the ENCODE Project Consortium [37] .
Publically available data [23, 38] were utilised to see whether GSTCD or INTS12 was differentially expressed during normal human lung development. Previously, human fetal lung tissues were obtained from National Institute of Child Health and Human Development tissue databases and microarray profiled to investigate the expression spanning different gestational ages. RNA samples from 38 subjects (estimated gestational age 7-22 weeks or 53-154 days post-conception) i.e. pseudoglandular (gestational age, 7-16 weeks) and canalicular (17-26 weeks) stages of development were included within the dataset. These data are available at NCBI Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo), GSE14334. The dataset was mined using Affymetrix probe sets; 220063_at, 1554518_at, 241126_at and 235387_at for GSTCD and 218616_at for INTS12 expression.
The presence of eQTL at 4q24 for GSTCD and INTS12 was investigated using the publically available eQTL datasets. The lymphoblastoid cell lines eQTL website at http:// www.hsph.harvard.edu/liming-liang/software/eqtl/ was used [21] . In addition, eQTL were also investigated using the Pritchard Lab eQTL website from the University of Chicago at http://eqtl.uchicago.edu/Home.html which hosts a browser summarising results from a collection of published eQTL studies.
Lung eQTL consortium methodologies
Subjects and genomic dataset. Non-tumour lung tissues were collected from patients who underwent lung resection surgery at three participating sites: Laval University (Quebec City, Canada), University of Groningen (Groningen, The Netherlands), and University of British Columbia (UBC, Vancouver, Canada). Whole-genome gene expression and genotyping data were obtained from these specimens. Gene expression profiling was performed using an Affymetrix custom array testing 51,627 non-control probe sets and normalised using RMA [39] . Genotyping was performed using the Illumina Human1M-Duo BeadChip array. Following standard microarray and genotyping quality controls, 1,111 patients were available including 409 from Laval, 363 from Groningen, and 339 from UBC. At Laval, lung specimens were collected from patients undergoing lung cancer surgery and stored at the "Institut Universitaire de Cardiologie et de Pneumologie de Québec" (IUCPQ) site of the Respiratory Health Network, Tissue Bank of the "Fonds de recherche du Québec -Santé" (www.tissuebank.ca). Written informed consent was obtained from all subjects and the study was approved by the IUCPQ ethics committee. At Groningen, lung specimens were provided by the local tissue bank of the Department of Pathology and the study protocol was consistent with the Research Code of the University Medical Center Groningen and Dutch national ethical and professional guidelines ("Code of conduct; Dutch Federation of Biomedical Scientific Societies"; http:// www.federa.org). At Vancouver, the lung specimens were provided by the James Hogg Research Center Biobank at St Paul's Hospital and subjects provided written informed consent. The study was approved by the ethics committees at the UBCProvidence Health Care Research Institute Ethics Board.
Correlation of mRNA expression levels of GSTCD and INTS12. GSTCD was evaluated by three probe sets on the Affymetrix array, while a single probe set was tested for INTS12. The 1,111 individuals that passed all quality controls filters were included in the analyses. The relationship between the mRNA expression values of the different probe sets testing GSTCD and INTS12 was assessed using Pearson's correlations.
Lung eQTL analysis for GSTCD and INTS12. eQTL analyses were performed in the 1,111 subjects. SNPs located 50 kilobases up-and down-stream of GSTCD and INTS12 were evaluated for association with their respective probe sets. Age, gender, smoking status, and the study site were included as covariates. Significant eQTL were those passing Bonferroni correction considering the number of SNPs tested for each gene.
Correlation of transcript levels with lung function. Correlations of transcript levels of GSTCD and INTS12 in the lung with percent predicted FEV 1 were investigated using Pearson's correlation. These analyses were performed with 848 subjects (a sub-set of the 1,111 available), for whom lung function data were available and which excluded individuals with airway disease which was non-obstructive or not due to smoking. The demographics of these 848 individuals are included in Table S5 . Accession: protein accession number; Chr: Chromosome; E value: Expect value (E), a parameter that describes the number of hits one can "expect" to see by chance when searching a database of a particular size. (DOCX) Table S2 . A. 100 "resistant" smokers whole exome resequencing. An exome re-sequencing project (results unpublished) identified 1 non-synonymous SNP and 1 synonymous SNP in the coding regions of INTS12 which were listed in dbSNP v137 but which were not in the 1000 Genomes Project imputation reference panel. Both SNPs occurred as a singleton call (1 heterozygote, no ALT allele homozygotes) in the 100 individuals. rs146172950 is listed as a triallelic SNP in dbSNP137 with reference allele C and alternative allele T (frequency 0.049%) originally identified and submitted by the NHLBI Exome Sequencing Project and alternative allele A (frequency 0.016%) subsequently identified and submitted by the 1000 Genomes Project. The alternative allele T was observed in the 100 resistant smokers exome sequencing project. rs144650579 is listed in dbSNP137 with reference allele T and alternative allele C (frequency 0.085%) originally identified and submitted by the NHLBI Exome Sequencing Project. B. Targeted sequencing of GSTCD/INTS12 region. A targeted sequencing study (results unpublished) identified two intronic SNPs in GSTCD that do not appear in 1000 Genomes Project. All the SNPs identified in INTS12 appear in 1000 Genomes Project imputation reference panel. rs113987854 is listed in dbSNP137 with reference allele T and alternative allele A originally identified and submitted by Complete Genomics. No population frequency is available for this SNP (only counts based on one individual have been submitted to dbSNP137). (DOCX) Table S3 . Transcription Factor sites identified via the ENCODE project Chip-Seq assay in the region: chr4:106609150-106654787 (hg build37). ChromStart: Start position in chromosome; ChromEnd: End position in chromosome; Name: name of transcription factor; Score: Score from 0-1000 (score for each peak, which reflects the posterior probability of the peak belonging to the irreproducible group). Search performed 30/01/2013. (DOCX) Table S5 .
Supporting Information
Clinical characteristics of 848 individuals participating in the eQTL study. Pre: pre-bronchodilator; Post: post-bronchodilator; Laval (Laval University, Canada), Groningen (University of Groningen, The Netherlands) and UBC (University of British Columbia, Canada) refer to the cohorts recruited from each centre. Data are presented as mean ± standard deviation. (DOCX) Table S6 . Fetal lung gene array data comparing GSTCD and INTS12 expression during pseudoglandular and canalicular stages of lung development. logFC: log-fold difference between 2 experimental groups; Average expression is between all samples; t: t-statistic describing differential expression; P Value: Unadjusted P value; Adjusted p value controls for false discovery rate; Beta-coefficient: log-odds ratio. n/s: no significance observed. Significant effects are shown in bold and italicised. (DOCX)
